Impeller optimization for a combined pump-oxygenator

描述(申请人提供)：肺部疾病是美国第三大死因。在美国，成人呼吸窘迫综合征(ARDS)每年困扰着大约15万名患者。肺病每年给美国经济造成的总支出为1480亿美元。虽然心脏病和癌症的治疗死亡率显著下降(自1979年以来心脏病的死亡率为36.6%)，但同期肺部疾病的死亡率上升了19.3%。目前对急性和慢性肺部疾病的现有治疗方法并不有效，并存在与之相关的各种问题。这项提议的目标是将我们在血泵和人工肺技术方面的独特技术优势与新的计算设计方法结合起来，设计和开发一种用于成人呼吸支持的创新的准心脏泵氧合器(PPO)。这项STTR提案建议开发的创新PRO基于紧凑、集成的叶轮泵和气体交换器的新概念，该概念结合了集成的泵送和主动混合原理，以实现良好的气体交换，并消除了天然右心室作为泵源的需要，就像被动灌流的人工肺一样。我们的建议是将马里兰大学人工器官实验室的技术转让给MC3公司，目的是开发一种紧凑而高效的泵-氧合器装置，其设计规格如下：(1)氧气传输速度为400毫升/分钟；(2)在100毫米汞的压力下，血液泵送能力高达6升/分钟；(3)总容量小于被动(即没有机械泵)人工肺的50%。我们这一阶段工作的目标是优化叶轮设计，以证明一体化泵氧功能的可行性和有效性，以及紧凑型PPO装置在体内的短期血液相容性。为了实现这些设计规范，我们建议在第一阶段工作中解决以下具体目标：1)优化PPO的叶轮设计，以实现气体传输性能和血液相容性；2)制造用于性能测试的PPO原型；3)对优化的PPO叶轮设计进行体外血液相容性实验；以及4)对优化的PPO叶轮设计进行短期体内实验。

DESCRIPTION (provided by applicant): Lung disease is America's third largest cause of death. Adult respiratory distress syndrome (ARDS) afflicts approximately 150,000 patients every year in the US. Lung disease costs the American economy $148 billion yearly in total expenditures. While treatment for heart disease and cancer has been marked by a significant fall in their rates of death (36.6% for heart disease since 1979), the rates of death from lung diseases rose by 19.3% during the same time period. Current available therapies for acute and chronic lung diseases have not been effective and have various problems associated with them. The goal of this proposal is to combine our unique technical strengths in blood pump and artificial lung technologies and new computational design approaches to design and develop an innovative paracorporeal pump-oxygenator (PPO) for adult respiratory support. The innovative PRO proposed for development by this STTR proposal is based on a novel concept of a compact, integrated impeller pump and gas-exchanger that incorporates an integrated pumping and active mixing principle for excellent gas exchange and eliminates the need for the native right ventricle to be the pumping source, as in passively perfused artificial lungs. Our proposal represents a transfer of technology from the University of Maryland Artificial Organs Laboratory to MC3 Inc. with the objective of developing a compact and efficient pump-oxygenator device with the following design specifications: (1) O2 transfer of 400 ml/min; (2) blood pumping capability of up to 6 liters/min against a pressure of 100 mmHg; (3) total volume less than 50% of a passive (i.e. with out mechanical pump) artificial lung. Our target of this Phase I effort is to optimize the impeller design in order to demonstrate the feasibility and efficacy of the integrated pumping-oxygenation functions and the short-term hemocompatibility of the compact PPO device in vivo. To achieve these design specifications, we propose to address the following specific aims in this Phase I effort: 1) optimize the impeller design of the PPO for gas transfer performance and hemocompatibility; 2) fabricate PPO prototypes for performance testing; 3) conduct in-vitro hemocompatibilty experiments on the optimized PPO impeller design; and 4) conduct short-term in-vivo experiments on the optimized PPO impeller design.